Locations
United States · Boston, MA, USA · West Street / River Street, Boston, MA, USA
industry
Biotechnology
Size
51-200 employees
Stage
Series C+
founded in
2014
Selux Diagnostics is developing a next generation phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the world’s deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. Selux NGP is the only platform capable of delivering personalized therapy results for all patients within a day of hospital entry, speeding this targeted treatment by an average of 2 days and as many as 4 days for patients infected.
Something looks off?On-site & Remote